Universe Pharmaceuticals INC Dossier - Source-backed chat

Universe Pharmaceuticals INC

UPCNASDAQ

SectorHealth Care

IndustryPharmaceuticals

Beta (adjusted)1.36

Intrinsic Value

Insufficient data for a value estimateNot enough reliable inputs to publish a fair value for this company yet.

Market Price $4.30Price as of 30 Sep 2026

Data confidenceNot applicable

Market Cap $21.6M

Enterprise Value −$31.5B

Shares Outstanding 5M diluted

Moat Rating None

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

Universe Pharmaceuticals INC (UPC) faces severe operational and financial headwinds, characterized by a multi-year decline in revenues, persistent net losses, and highly concentrated voting control under a newly implemented dual-class share structure. While the company maintains a cash-heavy balance sheet, its core business of manufacturing and distributing traditional Chinese medicine derivatives targeting the elderly in China has failed to generate positive operating cash flows. Furthermore, the company has a history of delayed SEC filings and Nasdaq compliance issues, making it a highly speculative and risky investment.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 20 Jun 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

$0.5025%

Further deterioration in sales, failure to comply with Nasdaq listing rules (such as minimum bid price or filing requirements), or severe regulatory actions in China lead to delisting from the Nasdaq Capital Market, wiping out minority shareholder value.

Base CaseCentral scenario

$3.0060%

The company continues to experience declining or stagnant revenues with persistent net losses. Operational cash burn continues to deplete its cash reserves, and the stock remains highly volatile with limited institutional interest.

Bull CaseUpside scenario

$5.0015%

A successful turnaround driven by the expansion of product lines, strategic partnerships in China's elderly healthcare market, and stabilization of raw material costs could restore revenue growth and lead to operating profitability.

Scenarios reflect our research view at the research date.

Key Investment Merits

Substantial cash and cash equivalents of approximately $33.59 million as of September 30, 2025, exceeding total liabilities.
Positioned in China's rapidly aging demographic sector, which presents long-term structural demand for elderly healthcare and traditional Chinese medicine products.

Key Investment Risks

Significant revenue contraction, declining from $32.31 million in FY2023 to $17.86 million in FY2025.
Persistent net losses, reporting a net loss of $3.67 million for the fiscal year ended September 30, 2025.
Extreme concentration of voting power, with CEO Gang Lai controlling approximately 75% of total voting power following the implementation of the dual-class share structure and subsequent equity grants in May 2026.
History of regulatory compliance issues, including Nasdaq delisting notices and delayed annual report filings.

Thesis Invalidation Triggers

Unexpected surge in sales of traditional Chinese medicine derivatives or third-party products leading to operating profitability.
Acquisition of the company or strategic investment by a major pharmaceutical group at a premium.
Successful commercialization of new high-margin biomedical drugs or medical instruments.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.